Araki E, et al. - In patients with type 2 diabetes and hypertriglyceridemia, researchers assessed the effectiveness and safety of pemafibrate over 52 weeks. For this investigation, patients were randomized to receive placebo or pemafibrate treatment at 0.2 or 0.4 mg/day over a 24-week period (treatment period 1). The assigned treatment continued until week 52, except that after week 24 (treatment period 2) the placebo was changed to pemafibrate 0.2 mg/day. According to results, triglyceride levels, non-high-density lipoprotein cholesterol, and total cholesterol levels fell steadily. On the other hand, high-density lipoprotein cholesterol levels increased over 52 weeks with pemafibrate treatments. This was the first study to demonstrate that, in patients with type 2 diabetes and hypertriglyceridemia, pemafibrate treatment significantly improved lipid abnormalities and was well tolerated for 52 weeks.